NCT06639503 Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau
| NCT ID | NCT06639503 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Chicago |
| Condition | Tibial Plateau Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 38 participants in total. It began in 2024-11-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators are conducting this research study to find better ways of treating pain following knee surgery. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if providing numbing medication to a nerve that controls pain in a larger area of the knee (a nerve block), might be better at post-operative pain control.
Eligibility Criteria
Inclusion Criteria: • Any adult patient (ages 18 and over) undergoing open reduction internal fixation of an acute isolated tibial plateau fracture Exclusion Criteria: * Subjects younger than 18 * Polytraumatized Subjects * Subjects with pathologic fractures * Subjects with tibial plateau fractures treated nonoperatively * Subjects with tibial plateau fractures treated operatively but with re-operations at the same site * Subjects with open fractures * Subjects with fracture-dislocations * Subjects with active or history of anxiety * Subjects with visual analog scale anxiety score ≥ 7 measured preoperatively * Subjects with chronic pain syndromes * Subjects with chronic opioid use * Subjects with illicit drug use disorder * Subjects with alcohol abuse disorder * Subjects with kidney disease precluding use of ketorolac * Subjects with liver disease precluding the use of acetaminophen * Subjects with allergy to acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opiates or local anesthesia * Subjects with inability to provide a visual analog scale score postoperatively * Subjects with contraindications to receiving peripheral nerve blocks, including relevant neurologic deficits, active infection at sites of injections - re-operation at the same site
Contact & Investigator
Anthony Christiano, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06639503 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tibial Plateau Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06639503 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06639503 currently recruiting?
Yes, NCT06639503 is actively recruiting participants. Contact the research team at anthony.christiano@bsd.uchicago.edu for enrollment information.
Where is the NCT06639503 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06639503 clinical trial?
NCT06639503 is sponsored by University of Chicago. The principal investigator is Anthony Christiano, MD at University of Chicago. The trial plans to enroll 38 participants.